Hemosol B0

Hemosol B0 is an injectable electrolyte solution containing calcium, lactic acid, magnesium, sodium, chloride ion, and hydrogen carbonate. It is supplied as a sterile solution for injection, intended for use in haemodialysis and intravenous administration. The product is marketed in the European Union and is prescribed by healthcare professionals to support acid‑base and electrolyte balance during renal replacement therapy. It also aids in patient fluid management.

Hemosol B0 is indicated for several clinical situations where electrolyte and acid‑base control are required.

- Hemodialysis procedures to replace lost electrolytes and maintain buffer capacity. - Acute renal failure when intravenous electrolyte supplementation is needed. - Peri‑operative fluid management in patients undergoing major surgery with renal risk. - Treatment of metabolic acidosis associated with renal insufficiency. - Electrolyte replacement in patients receiving large-volume parenteral nutrition. - Support of patients with chronic kidney disease during intermittent dialysis sessions.

Adverse reactions to Hemosol B0 are generally related to its electrolyte composition and infusion characteristics.

Common: - Mild nausea or vomiting during infusion. - Transient headache or dizziness. - Local irritation at the injection site, such as erythema or mild pain. - Temporary changes in serum calcium or magnesium levels that resolve without intervention. - Elevated serum chloride resulting in mild metabolic acidosis. - Minor fluctuations in sodium levels causing mild thirst.

Serious: - Severe hypercalcemia or hypermagnesemia leading to cardiac arrhythmias. - Acute metabolic alkalosis with significant pH shift. - Anaphylactic or severe hypersensitivity reactions, including bronchospasm. - Rapid fluid overload causing pulmonary edema. - Life‑threatening hyperkalemia if solution is mixed incorrectly. - Severe electrolyte imbalance resulting in seizures or coma.

When prescribing or administering Hemosol B0, clinicians should observe several precautionary measures to ensure patient safety.

- Verify patient electrolyte baseline values before initiation. - Adjust infusion rate according to individual fluid status and cardiac function. - Avoid use in patients with known hypersensitivity to any component of the solution. - Monitor serum calcium, magnesium, and acid‑base status regularly during therapy. - Use caution in patients with congestive heart failure or pulmonary edema risk. - Do not exceed recommended volume limits in pediatric patients. - Ensure compatibility with other intravenous solutions; avoid mixing with calcium‑containing drugs unless specifically indicated.

Hemosol B0 may interact with other medications or solutions administered concurrently.

Avoid: - Concurrent infusion of calcium‑containing medications that could cause precipitation. - Co‑administration with potassium‑sparing diuretics that may exacerbate hyperkalemia. - Mixing with blood products that contain citrate, which can alter calcium balance.

Use with caution: - Concurrent use of loop diuretics, requiring close monitoring of electrolytes. - Administration alongside bicarbonate‑containing solutions, which may increase risk of metabolic alkalosis. - Use with vasopressors, as rapid shifts in electrolytes can affect hemodynamic stability.